|Bid||0.00 x 900|
|Ask||0.00 x 1400|
|Day's range||146.71 - 152.12|
|52-week range||117.08 - 388.00|
|Beta (5Y monthly)||-0.08|
|PE ratio (TTM)||4.68|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 Jun 2022|
|1y target est||244.89|
Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.